Provention Bio Inc
F:2VB
Net Margin
Provention Bio Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
P
|
Provention Bio Inc
F:2VB
|
1.9B EUR |
-881%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
770.2B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
404.9B USD |
25%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.2B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
179.7B CHF |
25%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
167.5B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
213.1B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
140.9B USD |
13%
|
Provention Bio Inc
Glance View
Provention Bio Inc., a biopharmaceutical entity, emerged with a focused mission: pioneering the interception and prevention of immune-mediated diseases. The company identified a niche in the therapeutic landscape by addressing the root causes rather than merely managing symptoms. At its core, Provention Bio aimed to delay or halt the progression of autoimmune disorders, particularly Type 1 Diabetes (T1D), by leveraging immunotherapy. Their flagship product, teplizumab, stood as a testament to this strategy. This monoclonal antibody was designed to slow down the progression of T1D by modifying the immune system's response, thereby extending the period before insulin dependence begins in at-risk individuals. Rather than following the conventional path of reacting to fully manifested diseases, Provention Bio championed a proactive approach, capitalizing on early intervention. Financially, Provention Bio's business model revolved around developing and commercializing their innovative therapies, steering through regulatory approvals, and forming strategic partnerships. The company secured collaborations with larger pharmaceutical firms, like Sanofi, not only to bolster financial resources required for large-scale drug trials but also to leverage distribution channels once the therapies hit the market. Revenue streams were projected from licensing agreements, milestone payments, and, eventually, product sales upon successful commercialization. By addressing a significant unmet medical need, Provention Bio positioned itself to capitalize on the growing interest in disease prevention, while also offering hope to patients facing the realities of living with autoimmune diseases.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Provention Bio Inc's most recent financial statements, the company has Net Margin of -880.7%.
You don't have any saved screeners yet